Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
ODAC Decision for Olaparib/Abiraterone in mCRPC Likely to Impact Forthcoming Studies
May 12th 2023In an interview with Targeted Oncology™, Andrew J. Armstrong, MD gave a first-hand perspective on the discussion held during the recent ODAC meeting and explained what the discussion and vote mean for the future of olaparib plus abiraterone in metastatic castration-resistant prostate cancer.
Read More
Mosunetuzumab Maintains Efficacy/Survival Benefit in Elderly Patients With DLBCL
May 5th 2023In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.
Read More
Medical Meeting Places Spotlight on the Management of Breast Cancer
May 4th 2023In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed the key breast cancer topics during the Miami Cancer Institute Women’s Cancer Symposium and her presentation regarding HER2-positive breast cancer .
Read More
Adding Lenalidomide to Rituximab Consolidation Shows No PFS Improvement in MCL
May 3rd 2023In an interview with Targeted Oncology, Mitchell Smith, MD, PhD, discussed what the findings from the ECOG-ACRIN E1411 trial in patients with mantle cell lymphoma means for the future of the space, and where research is heading.
Read More
Orca-Q Elicits Compelling Data Among Patients Undergoing Haplo HSCT
April 20th 2023In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.
Read More
Behind the FDA Approval: Omidubicel for Blood Cancers in Need of HSCT
April 20th 2023In an interview with Targeted Oncology, Mitchell E. Horwitz, MD, discussed the FDA approval of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.
Read More
Radiation Plus Immune Checkpoint Blockade May Be an Alternative Option in SCLC
April 18th 2023In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.
Read More